Hoorn Nh

• Liposomal iRInotecan, Carboplatin or oXaliplatin in the first line treatment of esophagogastric cancer: a randomized phase 2 study (LyRICX) Ended recruitment
  2023-509287-26-00 4 2019-07-01 previously untreated metastatic or locally advanced esophagogastric ca
• HOVON 152 DLBCL. A phase II study evaluating the effect of DA-EPOCH-R induction followed by nivolumab consolidation in patients with newly d … Ended recruitment
  2022-501038-48-00 4 2018-07-26 Diffuse Large B-Cell Lymphoma
• Endocrine therapy plus CDK 4/6 inhibition in first- or second-line for hormone receptor positive advanced breast cancer - the SONIA study Ended recruitment
  2024-516204-42-00 5 2017-11-21 Breast cancer
• Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) Ended recruitment
  2023-507889-89-00 5 2016-02-19 Respiratory tract infection
• Biomarker discovery randomized phase IIb trial with carboplatin-cyclophosphamide versus paclitaxel with or without atezolizumaB as first-lin … Ended recruitment
  2024-516202-39-00 4 2013-10-10 Metastatic breast cancer
• GENPAD Ended
  2024-518122-33-00 6 2024-12-13 Peripheral Arterial Disease
• A clinical study of MK-0616 for people with high amounts of low-density lipoprotein cholesterol Ended
  2022-502782-14-00 5 2023-09-28 Heterozygous Familial Hypercholesterolemia (HeFH)
• A Study to Evaluate the Efficacy and Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Ended
  2023-507093-40-00 4 2022-01-27 Chronic Obstructive Pulmonary Disease (COPD)
• Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended
  2023-503673-38-00 5 2019-05-24 Adults at high risk of cardiovascular events without prior MI or strok
• Pembrolizumab Alone versUs pembrolizumab-chemotherapy in first LInE NSCLC (PAULIEN) Ended
  2024-516581-11-00 5 Advanced stage NSCLC

Showing 25–34 of 34 trials